Major Trial Tests CAC Scoring Versus Traditional Risk Scores for Statins

The CorCal Outcomes trial, published in September 2026 by the European Society of Cardiology, tested whether utilizing coronary artery calcium (CAC) scoring via CT scans could optimize statin initiation compared to traditional pooled cohort equations (PCE) risk scoring. Researchers evaluated 5,772 participants over an average of 4.2 years and found that the scan-based strategy resulted in far fewer statin recommendations and significantly higher medication adherence, while major cardiovascular events occurred in 2.7% of participants in both groups. The principal investigator, Dr. Joseph B. Muhlestein of Intermountain Health Care, noted that while the trial successfully demonstrated efficiency gains in statin adherence, it could not definitively prove noninferiority regarding cardiovascular outcomes. This limitation stemmed from lower-than-expected overall event rates during the follow-up period, reducing the statistical power necessary to validate equivalence between the two diagnostic strategies. Traditional PCE risk scoring recommended statin therapy more than three times as often as CAC scoring, yet adherence dropped to 23% in the traditional group compared to 62% in the CAC-guided group. This highlights a critical behavioral divide where direct visualization of plaque via medical imaging strongly motivates patients to maintain long-term preventive treatment regimens. Future clinical practice can leverage these insights to design refined randomized controlled trials comparing imaging-based biomarkers with algorithmic risk calculators. Healthcare providers should consider incorporating coronary artery calcium scoring to enhance patient compliance and target preventative medication to individuals with confirmed coronary plaque deposits.